Ghana Launches Pharmaceutical Manufacturing Framework Policy to Strengthen Industry Competitiveness, Investment and Local Production

The Government of Ghana has launched the Pharmaceutical Manufacturing Framework Policy, marking a significant milestone in the country’s efforts to accelerate industrial transformation, strengthen domestic pharmaceutical production and attract increased investment into the sector.

The policy, which received Cabinet approval in June 2026, provides a comprehensive framework to guide the growth and competitiveness of Ghana’s pharmaceutical manufacturing industry. It forms part of a broader package of industrial policies, including the Textile and Garment Manufacturing Policy and the Ghana Automotive Component Manufacturing Policy.

The Pharmaceutical Manufacturing Framework Policy was developed with technical support from the UK Government through the UK-Ghana Jobs and Economic Transformation (JET) Programme, as well as the German Development Cooperation through the PharmaVax Project, the European Union and other partners.

Launching the policy, Hon. Elizabeth Ofosu-Adjare, Minister for Trade, Agribusiness and Industry, said the policy marks the beginning of a new chapter for Ghana’s pharmaceutical industry and reflects the Government’s commitment to reducing dependence on imports and building a globally competitive manufacturing sector.

“Medicines are not ordinary goods. A country that cannot produce its own essential medicines leaves its health, economy and sovereignty vulnerable to decisions made elsewhere,” the Minister said. “This policy seeks to address critical constraints facing the industry, including high production costs, expensive financing, limited product diversification, and gaps in technology and skilled personnel.”

Ghana’s pharmaceutical sector is among the most developed in West Africa, with 38 licensed pharmaceutical manufacturing facilities employing more than 10,000 people directly. However, imported medicines continue to account for a significant share of domestic demand, presenting opportunities for increased local production, investment and export growth.

A key theme emerging from the launch was that policy development alone will not deliver Ghana’s ambitions. Speakers emphasised that success will depend on sustained implementation, investment and collaboration between government, industry, regulators, development partners and investors.

Speaking at the launch, Terri Sarch, UK Development Director at the British High Commission, underscored the importance of partnership in translating the policy into tangible results.

“Today’s launch is not only a significant achievement for Ghana, but also a testament to what can be achieved through sustained collaboration between government, industry and development partners,” she said. “The UK is proud to be one of the first development partners to support the development of this policy through the JET Programme.”

She noted that UK support has helped catalyse private investment across Ghana’s vaccine ecosystem, including the establishment of Ghana’s first vaccine-capable manufacturing facility, and highlighted broader JET Programme results of more than £130 million in investment mobilised and over 10,000 formal jobs created across Ghana.

“Policy alone cannot transform a sector,” Ms Sarch added. “Success will depend on continued collaboration, a competitive business environment, stronger skills, increased investment and regulation that supports innovation while safeguarding quality and safety.”

Addressing participants, Dr George Sabblah, Deputy Chief Executive Officer, Technical Operations at the Food and Drugs Authority (FDA), outlined ongoing regulatory and industry capacity-building measures designed to support implementation of the policy.

These include a roadmap to support local manufacturers to achieve current Good Manufacturing Practice (cGMP) standards by the end of 2027, initiatives to develop local technical expertise for the industry, and implementation of the restricted import list under Executive Instrument 496 to encourage local production of more than 200 pharmaceutical products.

“The success of this policy will not be determined by today’s launch, but by what we achieve collectively after today,” Dr Sabblah said.

Industry leaders also welcomed the policy as an opportunity to deepen local production and strengthen Ghana’s position as a pharmaceutical hub for West Africa and the continent.

Dr Lucia Addae, Executive Secretary of the Pharmaceutical Manufacturers Association of Ghana (PMAG), described the policy as providing clear direction for the industry and a pathway towards greater self-sufficiency and export competitiveness.

She called for continued focus on financing, market access, skills development, quality standards and local value-chain development, stressing that implementation would be critical to unlocking the policy’s full potential.

The launch also highlighted the importance of creating an enabling business environment. Speaking at the event, the German Ambassador to Ghana noted that governments cannot build successful pharmaceutical industries through policy alone, but can create the conditions necessary for private investment, innovation and manufacturing growth through effective regulation, reliable institutions and access to finance.

The launch reinforces ongoing collaboration between Ghana and the United Kingdom under the UK-Ghana Growth Partnership, which seeks to promote trade, investment and sustainable economic development. Pharmaceuticals has been identified as one of the sectors with strong potential to deepen bilateral cooperation while improving health security, creating jobs and attracting investment.

The UK continues to work with the Government of Ghana and industry stakeholders to develop new opportunities across the health and life sciences sector, including support for the proposed Legon Pharmaceutical Innovation Park, envisioned as a world-class hub for pharmaceutical manufacturing, research and innovation.

From Vision to Action: Plans for Ghana’s First Bio-Injectables Facility Take Shape

Ghana is taking a bold step toward pharmaceutical self-reliance. At a recent learning event, stakeholders in the pharmaceutical ecosystem gathered to explore the results of a feasibility study on building Ghana’s first bio-injectables manufacturing facility, a landmark project aimed at reducing dependence on imported medicines, strengthening local health systems, and creating high-quality jobs for Ghanaians.

Organised by the UK-funded Ghana Jobs and Economic Transformation (JET) programme and Quintex Pharma, the webinar brought together policymakers, industry leaders, and experts to discuss how Ghana can align policy, industry, and national interests to enrich discussions that could transform the country into a hub for advanced pharmaceutical production in West Africa. The webinar also provided an opportunity for participants to learn from best practices emerging from the initiative.

The proposed $60 million state-of-the-art plant is a joint venture between Ghana’s Quintex Pharma and South Korea’s GL Rapha. Currently, Ghana imports over 70% of its medicines, costing the country more than $300 million each year. The COVID-19 pandemic exposed the risks of relying on imports, especially during global supply chain disruptions. “Our goal is to build a facility that reduces Ghana’s dependence on imported medicines and strengthens our national health security,” said Dr. Kwesi Amissah-Arthur, CEO of Quintex Pharma.

The Ghana JET programme played a catalytic role in fostering a strategic partnership between Quintex Pharma and GL Rapha, paving the way for Ghana’s first bio-injectables manufacturing facility. Through UK-backed support, JET facilitated a feasibility study that assessed the plant’s financial viability, regulatory landscape, market demand, and environmental and social impacts. This partnership model reflects a broader commitment to building sustainable pharmaceutical capacity in Ghana. With the Ghana Food and Drugs Authority (FDA) now among the first two Sub Saharan African regulators to achieve WHO Maturity Level 3, the country is well-positioned to access larger regional markets and attract further investment.

Panelists at the event discussed challenges such as high business costs, access to financing, and the need for government incentives. They also highlighted the importance of research, skills development, and maintaining high manufacturing standards to ensure Ghana’s competitiveness.

Panelists stressed the need for competitive pricing, government support, and financing solutions to overcome high production costs and borrowing rates. They also underscored the importance of technology transfer, skills development, and maintaining strict Good Manufacturing Practices (GMP) to make Ghana a trusted pharmaceutical hub. 

“While the cost of doing business in Ghana presents challenges, it also highlights the urgency and opportunity to strengthen local competitiveness. By addressing key barriers, unlocking government incentives, and close financing gaps created by high interest rates, we can empower companies to thrive and reduce reliance on imports” noted Mr. Theophilus Arthur-Mensah – Senior Manager for Policy and Research, Association of Ghana Industries

The pharmaceutical sector is a government priority, especially post-COVID-19 which revealed supply chain vulnerabilities. “Guided by a Ghana Pharmaceutical Manufacturing Development Policy, we are committed to creating an enabling environment, ensuring market access, and driving incentives for R&D and technology transfer,” explained Mr. Kwasi Ofori-Antwi – Head of Strategic Anchor Industries, Ministry of Trade, Agribusiness, and Industry.

The Q&A session added depth to the webinar, with participants keen to understand how the initiative would support knowledge sharing, skills development, and technology transfer to boost local employment. A key takeaway was the emphasis on maintaining high manufacturing standards. 

“Good Manufacturing Practices (GMP) should be a core requirement for all pharmaceutical manufacturers, and a clear criterion for government procurement,” urged Reverend Jonathan Martey, Pharmaceutical Quality Assurance and Regulatory Affairs Consultant. “When companies commit to quality, they should be rewarded. If Ghana aims to lead in the regional pharmaceutical sector, we must consistently uphold a culture of quality. The long-term benefits are enormous.”

For Quintex Pharma, the long-term vision includes selling in Ghana, expanding to other West African countries, and eventually becoming export-focused. As CEO Dr. Kwesi Amissah-Arthur put it, “early and strong partnerships, competitive pricing, and maintaining world-class standards will make this work, because he who dares, wins.”

This initiative is more than a manufacturing project—it’s a bold move toward health security, economic growth, and regional leadership in pharmaceutical production.